Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
Nature Communications|May 10, 2025
T cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccinationJi-Li Chen, Beibei Wang, Yongxu Lu, et al.
The New England Journal of Medicine|October 29, 2025
Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A VaccineNaina McCann, Margarete Paganotti Vicentine, Narges Ebrahimi, et al.
The Journal of Experimental Medicine|May 25, 2016
Interferon-driven alterations of the host's amino acid metabolism in the pathogenesis of typhoid feverChristoph J Blohmke, Thomas C Darton, Claire Jones, et al.
AIDS (London, England)|May 31, 2024
MAVMET trial: maraviroc and/or metformin for metabolic dysfunction associated fatty liver disease in adults with suppressed HIVLeanne McCabe, James E Burns, Arash Latifoltojar, et al.
JAMA|April 20, 2016
Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical TrialIain D Milligan, Malick M Gibani, Richard Sewell, et al.
Lancet (London, England)|July 24, 2020
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M Folegatti, Katie J Ewer, Parvinder K Aley, et al.
The Lancet. Microbe|January 13, 2025
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection studyNavin Venkatraman, Daniel Silman, Duncan Bellamy, et al.
NPJ Vaccines|October 17, 2018
Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
The New England Journal of Medicine|January 17, 2019
Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax MalariaAlejandro Llanos-Cuentas, Marcus V G Lacerda, Tran T Hien, et al.
Lancet (London, England)|September 4, 2021
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, et al.
Pageof 8